Palbociclib
产品编号: DC8469
Featured
我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
Palbociclib (PD 0332991) 是选择性的 CDK4 和 CDK6 抑制剂，IC50 分别为11 nM，16 nM。Palbociclib 有潜力用于 ER 阳性和 HER2 阴性乳腺癌的研究。
| Cas No.: |
571190-30-2 |
| 名称: |
|
| 别名: |
PD0332991; PD-0332991; PD 0332991 |
| SMILES: |
C1(N=C2C(C(=C(C(N2C2CCCC2)=O)C(=O)C)C)=CN=1)NC1C=CC(N2CCNCC2)=CN=1 |
| 分子式: |
C24H29N7O2 |
| 分子量: |
447.53 |
| 纯度: |
|
| 保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
|
| In Vivo: |
|
| In Vitro: |
|
| References: |
Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib is a highly specific inhibitor of cyclindependent kinase 4 (Cdk4) (IC50, 0.011 μmol/L) and Cdk6 (IC50, 0.016 μmol/L), having no activity against a panel of 36 additional protein kinases. |
| Kinase Assay: |
|
| Cell Assay: |
|
| Animal Administration: |
|
| References: |
|
MSDS
COA
| LOT NO. |
DOWNLOAD |
|
|
| 2018-0101 |
|
询盘
